Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CorMedix Inc.CRMD · Entity 5280 | Chief Legal Officer | August 29, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CorMedix Inc.
Report date August 29, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 260,684 |
Reported balance
After 2026-08-29 transaction · row 1
1 source rowRow 1 · 2026-08-29 · Tax withholding · Disposed 8,424 · Balance 260,684 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 29, 2026 Filed Sep 2, 2026 00:16 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 8,424 | $8.30 | $69,919.20 |
DisclosureSEC source: 0001213900-26-096383 · ownership.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,684 Read SEC document |
| February 04, 2026 Filed Feb 7, 2026 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 36,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-013408 · ownership.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,108 F1 · price: Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 8,803 | $7.27 | $63,997.81 |
DisclosureSEC source: 0001213900-26-008480 · ownership.xml · nonDerivative · entry 2 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,102 Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 72,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-008480 · ownership.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,905 F1 · price: These shares represent restricted stock units granted on 01/23/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 11,333 | $12.16 | $137,809.28 |
DisclosureSEC source: 0001213900-26-001937 · ownership.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,085 Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:45 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001213900-25-087014 · ownership.xml · derivative · entry 4 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires 2033-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on 12/12/2023. These options vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:45 UTC | CorMedix Inc. CRMD · Entity 5280 | SaleCommon Stock | 400 | $12.82 | $5,128.00 |
DisclosureSEC source: 0001213900-25-087014 · ownership.xml · nonDerivative · entry 3 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,418 Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:45 UTC | CorMedix Inc. CRMD · Entity 5280 | SaleCommon Stock | 49,600 | $13.41 | $665,136.00 |
DisclosureSEC source: 0001213900-25-087014 · ownership.xml · nonDerivative · entry 2 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,818 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.83 to $13.82. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:45 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 50,000 | $3.30 | $165,000.00 |
DisclosureSEC source: 0001213900-25-087014 · ownership.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 21:11 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 69,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-084126 · ownership.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,298 F1 · price: These shares represent restricted stock units granted on 08/29/2025. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vested 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| August 29, 2025 Filed Sep 8, 2025 11:02 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 8,880 | $14.83 | $131,690.40 |
DisclosureSEC source: 0001213900-25-085280 · ownership.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,418 F1 · balance_after: On September 3, 2025, the Reporting Person filed a Form 4 that omitted the Issuer's withholding of common stock to satisfy the tax liability obligation of the Reporting Person. As reported in this amendment, the Issuer withheld 8,880 shares of common stock to satisfy the tax liability obligation of the Reporting Person. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 02:40 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 11,844 | $8.22 | $97,357.68 |
DisclosureSEC source: 0001213900-25-001355 · ownership.xml · nonDerivative · entry 2 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,612 Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 02:40 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-001355 · ownership.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,456 F1 · price: These shares represent restricted stock units granted on 01/02/2025. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:15 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-24-001355 · form4.xml · derivative · entry 3 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: These Restricted Stock Units were granted on 12/12/2023 and vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. F2 · derivative.expiration_date: These Restricted Stock Units were granted on 12/12/2023 and vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:15 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 6,044 | $8.77 | $53,005.88 |
DisclosureSEC source: 0000899140-24-001355 · form4.xml · nonDerivative · entry 2 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,456 Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:15 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899140-24-001355 · form4.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 12, 2024 Filed Dec 18, 2024 21:22 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 6,044 | $8.77 | $53,005.88 |
DisclosureSEC source: 0000899140-24-001360 · form4.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,956 F1 · balance_after: The reporting person has filed this amendment to restate the transaction reported in the Form 4 filed December 16, 2024 in order to correct the amount of Common Stock beneficially owned by the reporting person following the transaction and to remove a duplicative reference to the Restricted Stock Units reported in Table II. As reported in this amendment, the reporting person directly beneficially owns 43,956 shares of Common Stock following the reported transaction. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:05 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 200,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000929638-23-003428 · form4.xml · derivative · entry 2 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-12-11 F2 · derivative.exercise_date: These options were granted on 12/12/2023. These options vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 21:05 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000929638-23-003428 · form4.xml · nonDerivative · entry 1 Zelnick Kaufman Beth · CIK 0002004480 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · price: These Restricted Stock Units were granted on 12/12/2023. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.